MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL
The Prostate Jul 12, 2019
Nam RK, et al. - Via a cohort of 585 patients treated with radical prostatectomy, researchers investigated the mechanism of action of miR-139-5p, one of the downregulated microRNAs (miRNAs) recognized in a panel of five microRNAs (miRNAs) associated with biochemical recurrence and metastasis following prostatectomy. In prostate cancer, low miR-139 expression was markedly affiliated with many prognostic factors, including Gleason score, pathologic stage, margin positivity, and lymph node status. Among patients with high miR-139 expression, the cumulative incidence of biochemical recurrence and metastasis were significantly decreased. In comparison with control cells, a significant decrease in cell proliferation and migration was observed with the overexpression of miR-139 in prostate cancer cells with cells arrested in G2 of the cell cycle. IGF1R and AXL protein expression were repressed by miR-139 treatment, and it was reversed via the addition of miR-139 antagomir. In patients with localized prostate cancer, miR-139 was correlated with better prognosis, which could be mediated through the downregulation of IGF1R and/or AXL and associated signaling pathway components.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries